PBM

Business Context and Reporting Period

Company: Psyence Biomedical Ltd. (PBM)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended March 31, 2025
Business Overview: Psyence is a clinical-stage biotechnology company focused on developing botanical (nature-derived) psilocybin-based medicines for mental health disorders, specifically targeting Adjustment Disorder (AjD) in palliative care patients. The company has no approved products for commercial sale and has not generated any revenue to date. Operations are conducted primarily through subsidiaries in Canada and Australia.

Key Financial Metrics

Note: The 2025 net profit is non-operational, driven primarily by fair value gains on the conversion of debt to equity and warrant liability remeasurement.

Material Changes vs. Prior Period

• Profitability Shift: The company moved from a net loss of approximately $51.2 million in 2024 to a net profit of $1.0 million in 2025. This reversal is attributed to a $3.36 million fair value gain on convertible notes and a $0.71 million gain on promissory notes, offsetting operating losses.
• Liquidity Improvement: Cash balances increased significantly from $0.73 million to $6.14 million, resulting from equity financings (ELOC and PIPE) and the extinguishment of significant debt liabilities.
• Debt Extinguishment: Convertible note liabilities ($7.66 million in 2024) and promissory notes ($2.79 million in 2024) were fully extinguished in 2025 through debt-for-equity exchanges, reducing total liabilities from $12.1 million to $0.59 million.
• Expense Fluctuations: Research and Development (R&D) expenses decreased from $0.95 million to $0.34 million due to a transition in Contract Research Organizations (CROs). Conversely, General and Administrative (G&A) expenses more than doubled to $1.21 million, reflecting the costs of operating as a U.S.-listed public company.

Guidance, Outlook, and Risks

Outlook and Guidance: The company expects to incur significant losses for the foreseeable future as it advances its clinical pipeline. Management anticipates that existing cash ($6.17 million) will fund operations beyond 12 months from the filing date. The primary focus remains the Phase IIb clinical trial for PEX010 (psilocybin) in palliative care, with enrollment estimated to commence in the second half of 2025. Future funding requirements will depend on clinical trial outcomes and regulatory approvals.

Key Risks and Contingencies:

• Regulatory Uncertainty: Psilocybin is a Schedule I substance in the U.S. and heavily regulated globally. Approval is not guaranteed, and the FDA may not accept data from trials conducted outside the U.S. without an Investigational New Drug (IND) application.
• Capital Requirements: The company has no revenue and relies on equity and debt financing. Failure to secure additional funding could force delays or termination of clinical trials.
• Intellectual Property: The company does not own patents for naturally occurring psilocybin and relies on license agreements (e.g., with Filament Health Corp.) which may be terminated or expire.
• Nasdaq Compliance: The company recently underwent share consolidations to meet Nasdaq minimum bid price requirements. Continued compliance is necessary to avoid delisting.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $6.17 million cash balance against the estimated costs of the Phase IIb trial and ongoing G&A expenses.
• Debt Conversion Terms: Review the specific terms of the debt-for-equity exchanges that generated the 2025 profit to understand the dilution impact on existing shareholders.
• CRO Transition: Confirm the status of the transition from iNGEN to Southern Star Research and the timeline for Phase IIb enrollment.
• License Agreements: Examine the expiration dates and milestone obligations of the PEX010 license with Filament Health Corp.
• Share Consolidation: Note the impact of the 75-for-1 and 7.97-for-1 share consolidations on share count and per-share metrics.